BioCentury
ARTICLE | Clinical News

Nuvigil armodafinil: Phase III data

January 28, 2013 8:00 AM UTC

Top-line data from the double-blind, international Phase III Study 3072 trial in about 400 patients with major depression associated with bipolar I disorder showed that once-daily 150 mg Nuvigil as adjunctive therapy to mood stabilizers and/or atypical antipsychotics missed the primary endpoint of improving IDS-C30 score from baseline up to week 8 vs. placebo as adjunctive therapy. Teva said that Nuvigil demonstrated a numerical improvement on the endpoint vs. placebo, but could not be reached for details. ...